Navigation Links
Agendia Appoints Oncologist Richard A. Bender as Vice President and Chief Medical Officer
Date:4/1/2008

Leader in Molecular Cancer Diagnostics Strengthens U.S. Management Along

With U.S. Presence

AMSTERDAM, The Netherlands, April 1, 2008 /PRNewswire/ -- Agendia BV, a world leader in the rapidly evolving field of cancer molecular diagnostics, today announced the appointment of Richard A. Bender, MD, FACP to the position of vice president and chief medical officer (CMO). Dr. Bender, who will report directly to Chief Executive Officer (CEO) Dr. Bernhard Sixt, will be responsible for directing all medical activities within Agendia, playing an integral role in defining the strategic vision of the company as it expands its U.S. presence with an Agendia Inc. office in California in the coming months.

"We are very pleased to add a Board certified Oncologist of Dr. Bender's caliber to our management team," said Dr. Sixt. "As we continue to expand our U.S. presence and the use of our MammaPrint(R) diagnostic service by U.S.- based patients, we are confident that Dr. Bender's wealth of experience will play a critical role in the company's strategic planning and execution of our clinical programs."

"We are delighted to welcome Dr. Bender to the Agendia team," said Dr. Jan Groen, chief operating officer (COO) of Agendia. "His reputation and broad experience in the field of oncology, including treatment, drug development and genomic assays, will be an extremely valuable asset to our company as we increase our global presence."

"I am very excited to be joining Agendia at such a pivotal and exciting time in the company's development," said Dr. Bender. "Their FDA cleared breast cancer prognostic test MammaPrint clearly shows that Agendia is becoming an important diagnostic provider for the management of breast cancer. The company's promising oncology pipeline and its depth of expertise shows that the company is positioned very well to achieve its goal of bringing innovative cancer diagnostics to patient care."

Most recently, Dr. Bender was vice president and chief medical officer at Spectrum Pharmaceuticals, Inc., an oncology drug development company based in Irvine, CA. Dr. Bender has held key positions in the healthcare industry, including medical director for the oncology division of Quest Diagnostics, Inc., where he was involved in the development of new biomarkers and genomic assays. Prior to his tenure at Quest, he spent nearly two decades at Kaiser Permanente where he helped to develop their clinical oncology program.

Dr. Bender also served on the executive board of the San Diego Hospice and the American Cancer Society, and as a clinical instructor at the University of California, San Diego School of Medicine. He received his medical degree from the UCLA School of Medicine followed by specialty training in internal medicine at UCLA-Harbor General Hospital. He did his sub-specialty training in hematology/ oncology at the National Cancer Institute, where he spent three of his six years there as a senior investigator in the medicine branch.

Dr. Bender continues to serve as a clinical instructor at the University of California, Irvine School of Medicine, is a co-editor of the international oncology journal Anti-Cancer Drugs, and serves as an expert peer-reviewer in oncology for the Medical Board of California.

About Agendia BV

Agendia BV, located in Amsterdam, The Netherlands, is a world leader in gene expression analysis-based diagnostics. With three products on the market and an expanding market base, the company focuses on the development and commercialization of diagnostic tests using tumor gene expression profiling. Agendia was the first company to receive FDA clearance for its breast cancer test, MammaPrint(R), which predicts the risk of breast cancer recurrence. Its second microarray product, CupPrint(R)*, is a diagnostic test designed to identify the origin of the primary tumor in "Cancer of Unknown Primary." Agendia also recently presented its new colon cancer prognosis test, ColoPrint(R), which is currently undergoing further validation. Agendia maintains close ties with leading academic centers around the world to develop state of the art diagnostic tests for cancer. The company also offers its expertise to pharmaceutical and biotech companies focusing on development of highly effective precision therapeutics in oncology. For more information on Agendia, visit http://www.agendia.com.

* CupPrint(R) is based on a license to the TUO database of AviaraDx


'/>"/>
SOURCE Agendia BV
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Agendias MammaPrint(R), the Only FDA-Cleared Breast Cancer Prognosis Test, is Now Widely Available to U.S. Patients
2. Time Magazine Names Agendia Test a Best Invention of 2007
3. Investigational anti-restenosis drug pimecrolimus disappoints
4. Hauptman-Woodward Appoints Dr. Eaton Lattman CEO and Executive Director
5. Batesville Holdings, Inc., Appoints Doug Wilson Senior Vice President Human Resources
6. MAP Pharmaceuticals Appoints H. Ward Wolff to Board of Directors
7. Conatus Pharmaceuticals Appoints Anthony W. Fox, MD, Ph.D., as Chief Medical Officer
8. Management Consulting Group PLC Appoints Kurt Salmon Associates Chairman Mark Wietecha to its Board of Directors
9. Hiemstra Appoints Daniel C. Rosenman as Vice President of Research & Development
10. AMICAS Appoints Joseph D. Hill to Its Board of Directors and Promotes Kevin C. Burns to Senior Vice President and Chief Financial Officer
11. Digirad Corporation Appoints John W. Sayward to Its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... ... 31, 2016 , ... More than 80 representatives of the Hepatitis B ... Cancer Foundation held an event on National Hepatitis Testing Day outside of Philadelphia City ... the leading cause of liver cancer. , Foundation leaders and the citywide coalition they ...
(Date:5/31/2016)... ... May 31, 2016 , ... ... mix of advanced Artificial Intelligence (AI) and the latest in Clinical Patient ... center is integrating predictive analytic outputs directly into the clinical workflow. These insights ...
(Date:5/31/2016)... ... May 31, 2016 , ... Effective leaders not only drive service to the ... whole. On June 2, Northbound CEO Mike Neatherton and COO Paul Alexander will be ... opening plenary on “Leadership: The Journey to Authenticity” with Onsite Workshops CEO Miles Adcock ...
(Date:5/31/2016)... ... 31, 2016 , ... In his latest video, renowned AstroNumerologist ... humans. Using presidential candidate Donald Trump as an example, Kalsi describes the way ... not about adding numbers up,” says Kalsi. “It is about looking at each ...
(Date:5/31/2016)... ... 31, 2016 , ... TeaZa® Energy, LLC announces the launch of ... No Tobacco Day . The new flavor—Tropical TeaZa? Energy—will be available to customers ... , The new flavor is best described as a juicy, taste bud takeover. ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... , May 26, 2016 According ... "Medical Waste Management Market - U.S. Industry Analysis, Size, Share, ... management market in the U.S. was valued at US$ 5.89 ... CAGR of 3.4% from 2015 to 2023 to reach US$ ... analysis of current and emerging needle free drug delivery devices ...
(Date:5/26/2016)... , May 26, 2016 ... With Both Cost Savings and Overall Decreased ... (LSE: BTG), an international specialist healthcare company, has ... the 21st Annual Meeting of ISPOR (International Society ... of hepatocellular carcinoma (HCC) using yttrium-90 glass microspheres ...
(Date:5/26/2016)... Since its commercial introduction in ... life science tool for conducting genetic studies in a ... in its new report that the industry sits on ... by a range of new applications in the clinical ... http://photos.prnewswire.com/prnh/20140723/694805 ) , Since the Human ...
Breaking Medicine Technology: